Functional Characterization of N297A, a Murine Surrogate for Low-Fc Binding Anti-human CD3 Antibodies

Overview

Journal Immunol Invest

Publisher Informa Healthcare

Specialty Allergy & Immunology

Date 2009 Jan 28

PMID 19172487

Citations 15

Authors

Debra T Chao

Xiaohong Ma

Olga Li

Hyunjoo Park

Debbie Law

Affiliations

Soon will be listed here.

Abstract

Several low- or non-FcR binding anti-human CD3 monoclonal antibodies have been under investigation for the treatment of autoimmune diseases. To model the mechanism of action of these anti-human CD3 mAbs in the murine system, an Fc-modified anti-mouse CD3 antibody (N297A) was generated. N297A exhibited similar biological effects as Fc-modified anti-human CD3 antibodies including rapid, reversible reduction in peripheral leukocyte numbers, differential modulation of activated versus resting T cells, and reduced levels of induced cytokine release compared to the non-Fc-modified parent antibody. In an in vivo model of colitis induced by adoptive transfer of IL-10-deficient cells, administration of N297A significantly reduced body weight loss. As N297A shared many functional characteristics of non-FcR binding anti-human CD3 mAbs both in vitro and in vivo, it provides a means to model the mechanisms of action of Fc-modified anti-human CD3 antibodies in mouse.

Citing Articles

Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.

Long A, Xu H, Santich B, Guo H, Hoseini S, de Stanchina E J Hematol Oncol. 2024; 17(1):20.

PMID: 38650005 PMC: 11036555. DOI: 10.1186/s13045-024-01538-5.

Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D.

Slein M, Backes I, Garland C, Kelkar N, Leib D, Ackerman M Cell Rep Med. 2024; 5(2):101417.

PMID: 38350452 PMC: 10897633. DOI: 10.1016/j.xcrm.2024.101417.

Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models.

Takeshita M, Fukuyama H, Kamada K, Matsumoto T, Makino-Okamura C, Uchikubo-Kamo T iScience. 2022; 25(12):105596.

PMID: 36406861 PMC: 9664764. DOI: 10.1016/j.isci.2022.105596.

CLEC5a-directed bispecific antibody for effective cellular phagocytosis.

Kedage V, Ellerman D, Fei M, Liang W, Zhang G, Cheng E MAbs. 2022; 14(1):2040083.

PMID: 35293277 PMC: 8932924. DOI: 10.1080/19420862.2022.2040083.

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity.

Kamakura D, Asano R, Yasunaga M Pharmaceuticals (Basel). 2021; 14(11).

PMID: 34832954 PMC: 8619951. DOI: 10.3390/ph14111172.

References

Woodle E, Bluestone J, Zivin R, Jolliffe L, Auger J, Xu D . Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience. Transplant Proc. 1998; 30(4):1369-70. DOI: 10.1016/s0041-1345(98)00278-4. View

Vossen A, Tibbe G, Kroos M, van de Winkel J, Benner R, Savelkoul H . Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol. 1995; 25(6):1492-6. DOI: 10.1002/eji.1830250603. View

Wesselborg S, Prufer U, Wild M, Schraven B, Meuer S, Kabelitz D . Triggering via the alternative CD2 pathway induces apoptosis in activated human T lymphocytes. Eur J Immunol. 1993; 23(10):2707-10. DOI: 10.1002/eji.1830231050. View

Thistlethwaite Jr J, Stuart J, Mayes J, Gaber A, Woodle S, Buckingham M . Complications and monitoring of OKT3 therapy. Am J Kidney Dis. 1988; 11(2):112-9. DOI: 10.1016/s0272-6386(88)80192-6. View

Zhang X, Koldzic D, Izikson L, Reddy J, Nazareno R, Sakaguchi S . IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol. 2004; 16(2):249-56. DOI: 10.1093/intimm/dxh029. View

Carpenter P, Pavlovic S, Tso J, Press O, Gooley T, Yu X . Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol. 2000; 165(11):6205-13. DOI: 10.4049/jimmunol.165.11.6205. View

Cole M, Stellrecht K, Shi J, Homola M, Hsu D, Anasetti C . HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation. 1999; 68(4):563-71. DOI: 10.1097/00007890-199908270-00020. View

Li J, Davis J, Bracht M, Carton J, Armstrong J, Gao W . Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody. Int Immunopharmacol. 2006; 6(6):880-91. DOI: 10.1016/j.intimp.2005.12.009. View

Yu X, Bidwell S, Martin P, Anasetti C . Anti-CD3 epsilon F(ab')2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens. J Immunol. 2001; 166(9):5835-9. DOI: 10.4049/jimmunol.166.9.5835. View

10.

Sgro C . Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology. 1995; 105(1):23-9. DOI: 10.1016/0300-483x(95)03123-w. View

11.

Alegre M, Vandenabeele P, Depierreux M, Florquin S, Deschodt-Lanckman M, Flamand V . Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. J Immunol. 1991; 146(4):1184-91. View

12.

Jacobsohn D . Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs. 2002; 11(9):1271-80. DOI: 10.1517/13543784.11.9.1271. View

13.

Carpenter P, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P . A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005; 11(6):465-71. DOI: 10.1016/j.bbmt.2005.03.002. View

14.

Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P . Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol. 1990; 20(3):509-15. DOI: 10.1002/eji.1830200308. View

15.

Nimmerjahn F, Ravetch J . Antibodies, Fc receptors and cancer. Curr Opin Immunol. 2007; 19(2):239-45. DOI: 10.1016/j.coi.2007.01.005. View

16.

Yu X, Anasetti C . Enhancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenic anti-CD3epsilon F(ab')2. Transplantation. 2000; 69(1):104-12. DOI: 10.1097/00007890-200001150-00019. View

17.

Cole M, Anasetti C, Tso J . Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J Immunol. 1997; 159(7):3613-21. View

18.

Ochi H, Abraham M, Ishikawa H, Frenkel D, Yang K, Basso A . Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med. 2006; 12(6):627-35. DOI: 10.1038/nm1408. View

19.

Yu X, Levin S, Madrenas J, Anasetti C . Lck is required for activation-induced T cell death after TCR ligation with partial agonists. J Immunol. 2004; 172(3):1437-43. DOI: 10.4049/jimmunol.172.3.1437. View

20.

Hsu D, Shi J, Homola M, Rowell T, Moran J, Levitt D . A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. Transplantation. 1999; 68(4):545-54. DOI: 10.1097/00007890-199908270-00018. View